RecruitingNot ApplicableNCT06870812

Rapid Evacuation and Access of Cerebral Hemorrhage Trial


Sponsor

Emory University

Enrollment

600 participants

Start Date

May 27, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The main purpose of this study is to compare patients with a deep bleed in the brain undergoing surgery to patients receiving routine medical care. The standard treatment involves admission to the Intensive Care Unit (ICU) with close monitoring and blood pressure control. It also includes other medical (non-surgical) treatments to prevent more bleeding or another stroke. Sometimes, doctors will recommend surgery to remove the blood if medical treatment alone is not successful. There is evidence that doing minimally invasive surgery early-using a small opening in the skull to remove blood-may help some patients. Researchers aim to understand whether this surgery is better than current medical treatment, which may include surgeries to relieve pressure on the brain in some cases. This study, called REACH, is comparing usual medical care to early minimally invasive surgery so doctors can know which is better for patients.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria6

  • Age 18-70 years
  • Pre-randomization head CT demonstrating an acute, spontaneous, anterior basal ganglia primary intracerebral hemorrhage (ICH) (the anterior basal ganglia include the caudate, putamen, and pallidum to the capsula externa and excludes the thalamus)
  • ICH volume between 20 - 80 mL as calculated by an approved and standardized volumetric measurement
  • Study intervention can reasonably be initiated within 24 hours after the onset of stroke symptoms. If the onset is unclear, then the onset will be considered the time that the subject was last known to be well.
  • Glasgow Coma Score (GCS) 5 - 14
  • Historical Modified Rankin Score 0 or 1

Exclusion Criteria22

  • Ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, Moyamoya disease, venous sinus thrombosis, mass or tumor, hemorrhagic conversion of an ischemic infarct, recurrence of a recent (less than 1 year) ICH, as diagnosed with radiographic imaging
  • NIH Stroke Scale (NIHSS) less than or equal to 5
  • Bilateral fixed dilated pupils
  • Extensor motor posturing
  • Intraventricular extension of the hemorrhage is visually estimated to involve greater than 50% of either of the lateral ventricles
  • Primary thalamic ICH or basal ganglia hemorrhage with involvement \> 25% of thalamus
  • Infratentorial intraparenchymal hemorrhage including midbrain, pontine, or cerebellar
  • Use of anticoagulants that cannot be rapidly reversed (i.e., criteria is met if investigators are confident that clinically significant coagulopathy is not present after targeted correction)
  • Evidence of active bleeding involving a retroperitoneal, gastrointestinal, genitourinary, or respiratory tract site
  • Uncorrected coagulopathy or known clotting disorder
  • Known platelet count less than 75,000 or known international normalized ratio (INR) greater than 1.4 after correction
  • Patients requiring long-term anti-coagulation that needs to be initiated less than or equal to 5 days from initial ICH
  • End-stage renal disease
  • Patients with a mechanical heart valve
  • End-stage liver disease
  • History of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
  • Positive urine or serum pregnancy test in female subjects without documented history of surgical sterilization or post-menopausal
  • Known life expectancy of less than 6 months before ICH
  • No reasonable expectation of recovery, do-not-resuscitate (DNR), or comfort measures only before randomization
  • Participation in a concurrent interventional medical investigation or clinical trial. Patients in non-interventional/observational studies are eligible
  • Inability or unwillingness of the subject or legal guardian/representative to give written informed consent
  • Homelessness or inability to meet follow-up requirements

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURESurgical management

Following randomization into the surgical arm, a competency-trained neurosurgeon will perform the MIPS for clot evacuation with strict adherence to the Surgical Manual of the CSG. Image interpretation, patient position, anesthetic plan, stereotactic navigation registration, exoscopic positioning, access, optics, resection, and hemostasis are detailed in the Surgical Manual of the CSG. The OR arrival time should occur \<24 hours from the last known normal (LKN) with a goal of arrival in less than 8 hours from the last known normal.

OTHERMedical Management

Following randomization into the medical arm patients will be treated following the Medical Manual of the CSG. The Medical Manual has been adapted by the REACH Executive Committee (REC) from the current American Heart Association (AHA) and American Stroke Association (ASA) Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Whenever clinically feasible, the CSG should be followed as it represents a template for the care of these subjects. The Medical Manual details specialty level of care, including intensive care placement, blood pressure control, hemostasis and coagulopathy, anemia, deep venous thrombosis and pulmonary embolism prophylaxis/treatment, glucose management, temperature management, seizure prophylaxis, intracranial pressure monitoring and management, intraventricular hemorrhage (IVH)/obstructive hydrocephalus management, cerebral edema, decompressive hemicraniectomy, nutritional support, respiratory support, and comfort care.


Locations(21)

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Stanford University Medical Center

Palo Alto, California, United States

Baptist Health Jacksonville FL

Jacksonville, Florida, United States

Baptist Health South Florida

Kendall, Florida, United States

Jackson Memorial Hospital (JMH)

Miami, Florida, United States

Grady Memorial Hospital

Atlanta, Georgia, United States

Emory Hospital Midtown

Atlanta, Georgia, United States

Emory University Hospital (EUH)

Atlanta, Georgia, United States

Rush University

Chicago, Illinois, United States

Endeavor Health, Northshore

Evanston, Illinois, United States

Goodman Campbell Brain and Spine

Carmel, Indiana, United States

University of Kentucky

Lexington, Kentucky, United States

Johns Hopkins School of Medicine

Baltimore, Maryland, United States

University of Missouri

Columbia, Missouri, United States

Albany Medical Center

Albany, New York, United States

SUNY Upstate Medical University

Syracuse, New York, United States

Montefiore Medical Center/Albert Einstein School of Medicine

The Bronx, New York, United States

The Ohio State University

Columbus, Ohio, United States

ProMedica Toledo Hospital

Toledo, Ohio, United States

Rhode Island Hospital/Brown University Health

Providence, Rhode Island, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06870812


Related Trials